PositiveID Corporation (fka PSID)

[Peace-maker]

dont see a reason to get worked up over someone saying that theyre going to buy a bunch of shares. I'd think that that's actually good for our company, no?

@robsct

I guess you were referring to me regarding the comment about the "armchair experts" lol. I don't know why you would say that, since I hoped to make it clear that I am not a PhD-level expert in this field and do not know the specifics of the actual systems to be used in the BioWatch Gen 3 testing.

However, I didn't pull those bits about xMAP technology out of nowhere. I may not be an expert, but I do have background in molecular biology laboratory techniques. The xMAP technology is no push-over, at least in a clinical/laboratory setting. Here is some actual literature regarding xMAP:

http://www.ncbi.nlm.nih.gov/pubmed/22852821

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286996/

These are just two of the many scientific articles detailing the capabilities of the xMAP in general. However, like I said, there is far more to having a successful BioWatch Gen3 system than having a good laboratory technique such as xMAP. Implementation is of utmost importance. I just wanted to point out that the potential is there. it just is a matter of how it is integrated into a complete system (like how our qPCR and immunoassay are finely implemented into the M-BAND unit). In fact, I even pointed out before how NG put 6-20+ rather than 100+ on their brochure - that could be a sign that theyre having trouble maximizing the effectiveness of xMAP in a system that has to meet the demanding requirements of BioWatch 3. who knows

I just thought that it was important to us, as invetors, to know what we could be up against. the amount of information required to bring different people to the same level of conviction varies from person to person.